bioklone产品代理

Custom polyclonal antibodies

Custom monoclonal antibodies Hybridoma banking

Assay development services

Drug validation using antibodies

Bioklone Biotech Private Limited is an ISO 9001:2015 certified bioservice provider that specializes in the development of customized antibodies and assays. It has over 300 clients across various sectors including academia, R&D divisions of hospitals, diagnostic and pharma companies, in India and abroad. Ever since its inception in 2006, the vision of Bioklone has been to be among the preferred antibody companies in the world. Bioklone was awarded “Best Custom Antibody Development Specialists-India” award in Global Health and Pharma-Technology awards 2019. This recognition has been possible because of the company’s unique selling propositions including its end-end services, customer centric approach, timely deliveries, high quality and reliable services.

Bioklone has successfully developed custom polyclonal and monoclonal antibodies to over 1000 antigens including proteins, peptides, polysaccharides, drugs, small molecules and whole cells. Among the several challenging antibodies developed by Bioklone, are the highly specific antibodies to modifications at certain amino acids along the target protein, including acetylation, methylation, cleavage, mutation and phosphorylation. In addition, Bioklone has developed custom antibodies to several vaccines, biomarkers for conditions including cancers, myocardial infarction, genetic disorders and rare diseases as well as plant, veterinary and human pathogens. As a contract research organization, Bioklone offers end-to-end services, including peptide designing, gene cloning, expression and purification of recombinant proteins, development of antibodies in rabbits, mice and chicken, antibody purification, labelling and fragmentation, development of recombinant antibodies, assay development solutions and development of diagnostic kits. In addition, Bioklone also carries out in vitro assays using cell-lines to study cell viability/proliferation. Having carved its niche in the custom antibody market, Bioklone is now foraying into development of human and humanized antibodies.